Effect of pravastatin on development of left ventricular hypertrophy in spontaneously hypertensive rats

Tsung-Ming Lee,¹ Mei-Shu Lin,² Tsai-Fwu Chou,³ Chang-Her Tsai,⁴ and Nen-Chung Chang⁵

¹Cardiology Section, Department of Medicine, Taipei Medical University and Chi-Mei Medical Center, Tainan; ²National Taiwan University and Department of Pharmacy, National Taiwan University Hospital, Taipei; ³Department of Surgery, Municipal Jen-Ai Hospital, Taipei; ⁴Cardiology Section, Department of Medicine, National Taiwan University Hospital, Taipei; and ⁵Cardiology Section, Department of Medicine, Taipei Medical University and Hospital, Taipei, Taiwan

Submitted 4 May 2004; accepted in final form 19 January 2005

Lee, Tsung-Ming, Mei-Shu Lin, Tsai-Fwu Chou, Chang-Her Tsai, and Nen-Chung Chang. Effect of pravastatin on development of left ventricular hypertrophy in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 289: H220–H227, 2005. First published January 21, 2005; doi:10.1152/ajpheart.00417.2004.—Endothelin (ET)-1 has been implicated in the development of cardiac hypertrophy. We investigated the effect of pravastatin on development of ventricular hypertrophy in spontaneously hypertensive rats (SHR) and whether the attenuated hypertrophic effect was via reduced ET-1 expression. Normolipidemic SHR were treated with one of the following therapies for 8 wk: vehicle, the nonselective ET receptor antagonists bosentan, pravastatin, mevalonate, hydralazine, or combination of pravastatin + mevalonate from the age of 8 wk at the very early stage of cardiac hypertrophy. Treatment with bosentan and pravastatin significantly decreased left ventricular mass index for body weight and cardiomyocyte sizes isolated by enzymatic dissociation. The myocardial ET-1 levels and preproET-1 mRNA assessed using real-time quantitative RT-PCR were significantly higher (both \( P < 0.001 \)) in the SHR compared with Wistar-Kyoto rats. The increased tissue ET-1 levels can be inhibited after pravastatin administration. Immunohistochemical analysis confirmed the changes of ET-1. Left ventricular mass index for body weight correlated positively with tissue ET-1 levels (\( P = 0.0004 \)). A dissociation between the effects of blood pressure and cardiac structure was noted, because pravastatin and hydralazine reduced arterial pressure similarly. Pravastatin-induced effects were reversed by the addition of mevalonate. In conclusion, these results suggest a crucial role of cardiac endothelin system in the early development of ventricular hypertrophy in the SHR. Pravastatin is endowed with cardiac antihypertrophic properties that are independent of its hemodynamic and hypolipidemic effects and appear to be related to their capacity to decrease cardiac ET-1 levels, which is linked to mevalonate metabolism.

cardiomyocytes; endothelin-1; immunohistochemistry

EPIDEMIOLOGICAL STUDIES have demonstrated that increased left ventricular (LV) mass is a risk factor of cardiac morbidity and mortality in patients with hypertension (24). Previous data revealed that LV mass regression reduced cardiovascular complications (11). Hypertrophied myocardium has been shown to generate arrhythmias more readily than normal tissue. Agents that cause the regression of ventricular hypertrophy have been shown to decrease the susceptibility of ventricular arrhythmias (2). Thus the use of LV mass to stratify risk and target antihypertensive therapy has been proposed. To more effectively prevent cardiac hypertrophy and more successfully apply therapeutic interventions, it is important to better understand the factor(s) involved in ventricular growth at the early stage of cardiac hypertrophy, rather than at the established stage, so that therapeutic interventions can be more successfully applied.

Endothelin (ET)-1 gene expression is enhanced in heart in spontaneously hypertensive rats (SHR) (36), an experimental model of genetic hypertension. In SHR, pressure overload initially developed at 8 wk, followed by an active phase of hypertrophic growth between 16 and 20 wk (3). ET-1, a potent growth-promoting peptide derived from endothelial cells, is also produced by cardiac myocytes (30). ET-1 acts as a key autocrine/paracrine mediator to trigger the hypertrophic signaling pathways by activation of extracellular signal-regulated kinase in myocardium via activation of ETA/B receptor (43). ET receptor blockade attenuates ventricular hypertrophy (9). Thus treatment with ET antagonists appears to be an attractive alternative to attenuate ventricular hypertrophy.

Pravastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (statin), blocks the mevalonate pathway, reducing cholesterol biosynthesis. Epidemiological studies have demonstrated that the benefit of statin treatment extends to patients with normcholesterolemia (41). Statins exert pleiotropic properties and interfere with signal pathways for hypertrophy, effects that may contribute to their beneficial effects on ventricular hypertrophy (41). Statins have been shown to inhibit ET-1 and to subsequently prevent cellular hypertrophy (41). There are many kinds of statins used clinically that show differences in pharmacological lipophilicity, structure, and solubility. Because lipophilic statins may enter cardiomyocytes, there was a difference in their potency to inhibit mevalonate synthesis in extrahepatic cells (42), which could lead to a different effect on cardiac hypertrophy between lipophilic and hydrophilic statins. Thus, although lipophilic statins have been shown to attenuate ventricular hypertrophy (1, 12), the effects cannot be extrapolated to hydrophilic statins. Whether pravastatin, a hydrophilic statin, has an effect on ventricular hypertrophy remains unknown in SHR. The purpose of this study was to investigate the effect of pravastatin on cardiomyocyte sizes and the role of circulating and cardiac ET systems at the early hypertrophic phase of SHR. To further confirm the role of chronic endothelin activation in the prevention of pravastatin-induced ventricular hypertrophy, we assessed the effect of the nonselective ETA/B receptor antagonist bosentan. We also explored the downstream functional significance of reduced ventricular hypertrophy by ventricular pacing.
METHODS

Experimental animals. Male normocholesterolemic SHR had free access to food and water. At 8 wk of age at the very early stage of cardiac hypertrophy, SHR were randomly allocated to one of six groups and treated for 8 wk with vehicle, the nonselective ET receptor antagonist bosantan (10 mg/kg per day), pravastatin (5 mg/kg per day), mevalonate (50 mg/kg per day), hydralazine (10 mg/kg per day), or a combination of pravastatin and mevalonate. The dose of pravastatin used in this study was derived from previous experiments in which pravastatin restored the infarct size-limiting effect of ischemic preconditioning in hyperlipidemic rabbits (39). Because pravastatin has a blood pressure-lowering effect, hydralazine was used to determine the degree to which this decrease in blood pressure is responsible for attenuating cardiac hypertrophy. To further confirm the role of chronic ET activation in the progression of ventricular hypertrophy, we used the nonselective ET<sub>A</sub>C receptor antagonist bosantan at a dose of 10 mg/kg per day (Actelion Pharmaceuticals, Allschwil, Switzerland). The therapeutic efficacy of this dose has been previously demonstrated without hypotensive effects (27). The drugs were dissolved in drinking water, and the concentration was adjusted for the daily water intake and body weight to obtain the target dosage. In each treated group, drugs were withdrawn ∼24 h before the experiments to eliminate their pharmacological actions. One control group of age-matched normotensive Wistar-Kyoto (WKY) rats received no treatment. All the procedures were approved by the Institutional Animal Care and Use Committee and the Institutional Review Board of Chi-Mei Medical Center.

Hemodynamics and induced arrhythmias. Functional parameters were measured in anesthetized rats at the end of the study. Using a 2-F micromanometer-tipped catheter (model SPR-407; Millar Instruments, Houston, TX) inserted through the right carotid artery, we measured LV systolic and diastolic pressure as the mean of measurements of five consecutive pressure cycles. The maximal rate of contraction (±dP/dt) and relaxation (−dP/dt) was measured. Next, the heart was rapidly excised and suspended for retrograde perfusion with a Langendorff apparatus. Each heart was perfused with a noncirculating modified Tyrode solution containing (in mM) 117.0 NaCl, 23.0 NaHCO<sub>3</sub>, 4.6 KCl, 0.8 NaH<sub>2</sub>PO<sub>4</sub>, 1.0 MgCl<sub>2</sub>, 2.0 CaCl<sub>2</sub>, and 5.5 glucose, equilibrated at 37°C and oxygenated with a 95% O<sub>2</sub>-5% CO<sub>2</sub> gas mixture. The perfusion medium was maintained at a constant temperature of 37°C with a peristaltic pump at a constant flow of 4 ml/min. Epicardial electrograms were recorded using an atratranatic unipolar electrode placed on the epicardial surface of the right atrium and anterior LV wall 2 mm below the circumflex artery. A bipolar pacing electrode was placed near the apex of the heart on the anterior epicardial surface of the right ventricle. Atrial and ventricular epicardial electrocardiograms were continuously displayed on a Gould recorder at a chart speed of 500 mm/s and a Hewlett-Packard oscilloscope (model 54503A) at a sweep speed of 100 mm/s.

After isolation, the hearts were observed for 20 min to allow stabilization of hemodynamics. During the period, spontaneous arrhythmias were recorded. Induced arrhythmias were effected using an electrical Bloom stimulator. Stimulation intensity was twice the threshold, and stimulus length was 5 ms. The protocol for pacing and an arrhythmia scoring system were used as previously described (22).

Immunohistochemical analysis of ET-1. To investigate the spatial distribution of ET-1, we performed immunohistochemical staining on LV muscle. At completion of the electrophysiological tests, the heart was then rapidly divided into right and left atria and right and left ventricles. Each tissue was then weighed individually. LV muscle was snap frozen in liquid nitrogen and embedded in OCT compound (Tissue-Tek), and cryosections were prepared at a thickness of 7 μm. The slides containing the sectioned tissues were rehydrated in 0.01% sodium bicarbonate at pH 7.4. Sections were blocked with 0.1 mM 1-lysine in PBS containing 0.1% Triton X-100 for 45 min. Tissues were incubated with a rabbit polyclonal anti-ET-1 antibody (Immuno Biological Lab, Gunma, Japan) at 1:200 dilution in 0.5% BSA in PBS overnight at 37°C. Immunostaining with ET-1 antibodies was performed using a standard immunoperoxidase technique (N-Histofine Simple Stain MAX PO kit; Nichirei, Tokyo, Japan). The antibody used had been tested for specificity in the rat. Negative controls were performed by omitting the primary antibody.

Real-time RT-PCR. Real-time quantitative RT-PCR was performed from LV samples obtained with the TaqMan system (Prism 7700 sequence detection system; PE Biosystems) as described previously (23). For ET-1, the primers were 5′-TGCTGTTTTGTGTGCTTTCCAAA-3′ and 5′-CAAAGGATGCTTAGGTCAAGG-3′. For glyceraldehyde-3-phosphate-dehydrogenase (GAPDH), the primers were 5′-GTTTACACCACATGGAGAACGGC-3′ and 5′-GGC-ATGGACTGTGGTCATGAG-3′. For quantification, ET-1 expression was normalized to the expressed housekeeping gene GAPDH. Reaction conditions were programmed on a computer linked to the detector for 40 cycles of the amplification step.

Plasma and tissue levels of ET-1. Because of a local release of ET-1 and a poor correlation between plasma and tissue ET-1 levels, blood samples from the aortic root and the tissue from the LV were obtained for measurements of systemic and local ET-1 levels at the end of the study. For the measurement of cardiac ET-1 levels, the apical two-thirds of the LV was immediately homogenized with a Polytron homogenizer for Triton-X, boiled for 7 min, and centrifuged at 20,000 × g for 30 min at 4°C. After measurement of the protein concentration (in pg/mg), the supernatant was stored at −70°C until use. Plasma ET-1 concentration was measured by collecting 4 ml of blood in test tubes containing 2% EDTA (80 μl/ml blood). Blood samples were immediately centrifuged at 3,000 × g for 10 min, and the plasmas were stored at −70°C until further analysis was performed. ET-1 was measured using immunoassay (R&D Systems, Minneapolis, MN). Plasma (1 ml) was acidified with 3 ml of 4% acetic acid, and ET-1 was extracted with a Sep-Pak C-18 cartridge. The detection limit was 1 pg/ml for ET-1. Intra-assay and interassay coefficients of variation were 4.5 and 6.6%, respectively.

Cell isolation. Because cardiac hypertrophy is a combination of reactive fibrosis and myocyte hypertrophy, we measured cardiomycocyte sizes from the LV in addition to using myocardial weight to avoid the interference of nonmyocytes. Because immunohistochemical analysis does not permit quantification of cardiomycocyte sizes, additional groups of rats (n = 5 in each group) were used for measurement of cell sizes. Myocytes were enzymatically isolated according to previously described techniques (23). Briefly, the rats were heparinized, and heart was excised and perfused at a constant flow of 8 ml/min by using a modified Langendorff technique at 37°C with a nominally Ca²⁺-free, oxygenated Tyrode solution (pH 7.4) containing (in mM) 137 NaCl, 5.4 KCl, 1.1 MgCl<sub>2</sub>, 11 dextrose, and 10 HEPES. After 5 min of equilibration, the perfusion was changed to the same solution containing 0.34 mg/ml collagenase (type II; Sigma Chemical, St. Louis, MO). After 8–10 min of digestion, the residual enzyme-containing solution was cleaned by 5 min of perfusion with 0.2 mM Ca²⁺ Tyrode solution. The heart was then removed from the cannula, and the LV was mechanically dispersed. Random high-power fields of the rodlike relaxed myocytes with clear striations were selected in phase-contrast illumination mode of confocal microscopy (LSM-410 Invert; Zeiss) to eliminate selection bias. At least 100 cells from each section were selected for measurement of cell area, length, and width, and mean values were used as an individual value for each section.

Statistical analysis. Results are presented as means ± SD. Differences among the groups of rats were tested using two-way ANOVA. Subsequent analysis for significant differences between the two groups was performed with a multiple comparison test (Sheffe’s method). Electrophysiological data (scoring of programmed electrical stimulation-induced arrhythmias) were compared using a Kruskal-Wallis test followed by a Mann-Whitney test. An interaction term of stimulation-induced arrhythmias was compared using a Kruskal-Wallis test followed by a Mann-Whitney test. An interaction term of stimulation-induced arrhythmias was compared using a Kruskal-Wallis test followed by a Mann-Whitney test.
trophy and the tissue ET-1 levels was assessed using Pearson’s correlation coefficient. The significant level was assumed at a value of $P < 0.05$.

**RESULTS**

Pravastatin does not lower serum cholesterol in rats, consistent with the notion that compensatory increases in hepatic enzyme production were observed in rats treated with statins. These data indicate the nonlipid effect of pravastatin on ventricular hypertrophy.

**Hemodynamic data.** During the 8-wk treatment period, pravastatin decreased systolic blood pressure by 39 mmHg without, however, normalizing it (Table 1). Chronic antihypertensive treatment for 8 wk with hydralazine led to a similarly lower systolic blood pressure compared with pravastatin-treated SHR. Heart rate did not differ among all groups. The maximal rate of LV pressure rise ($+\text{dP/dt}$) was significantly increased in SHR compared with WKY rats.

**Morphometric studies.** Chronic drug treatment did not modify the increase of body weight with age. Table 1 shows LV weight-to-body weight ratios of animals from each group. By the end of the treatment period, body weights were similar in the SHR groups. Untreated SHR showed LV hypertrophy, with a significant increase of 40% in the ratio of LV weight to body weight compared with WKY rats. Compared with untreated SHR, bosentan and pravastatin decreased heart weight-to-body weight ratios by 7% and 8%, respectively ($P = 0.02$ and 0.01). Despite producing similar antihypertensive effects, hydralazine given to SHR showed a significant increased LV weight compared with those treated with pravastatin.

To characterize the cardiac hypertrophy on a cellular level, we isolated cardiomyocytes from different treated groups (Table 2). The cells isolated from untreated SHR group were smaller than that of vehicles (8 and 13%, respectively, both $P < 0.05$). Conversely, the rats to which mevalonate was administered developed cardiomyocyte hypertrophy greater than that in the pravastatin-treated group alone.

**Electrophysiological stimulation.** To further elucidate the physiological effect of attenuated cardiomyocyte hypertrophy, we performed ventricular pacing. Arrhythmia scores in WKY rats were very low (0.2 ± 0.4). In contrast, ventricular tachyarrhythmias consisting of ventricular tachycardia and ventricular fibrillation were inducible by programmed stimulation in SHR (Fig. 1). Bosentan and pravastatin treatment showed a significant reduction in arrhythmia scores compared with those treated with the vehicle, mevalonate, hydralazine, and a combination of pravastatin and mevalonate.

**Circulating and myocardial ET-1 levels and preproET-1 mRNA.** Circulating and myocardial ET-1 levels are shown in Table 1. There were significantly higher circulating and myocardial ET-1 levels in SHR compared with WKY rats (1.42 ± 0.41 vs. 0.48 ± 0.17 pg/ml for circulating ET-1 levels, $P < 0.0001$; 2.69 ± 0.70 vs. 1.24 ± 0.62 pg/mg tissue for myocardial ET-1 levels, $P = 0.0001$). Pravastatin administration attenuated the increased ET-1 concentrations, which were reversed after the addition of mevalonate.

As shown in Fig. 2, myocardial levels of preproET-1 mRNA were on average 3.3-fold higher in SHR than in WKY rats ($P < 0.0001$). This overexpression was attenuated by pravastatin administration. Thus the mRNA levels of preproET-1 changed in parallel to the tissue peptide levels, implying that the production of preproET-1 is a critical regulation step for its local activation.

**Immunohistochemical analyses.** To reveal the localization of cells containing the mature ET-1 peptide, we performed immunohistochemistry. Immunohistochemical analysis of the LV revealed the presence of ET-1 immunoreactivity in the myocardial tissue (Fig. 3). Stronger ET-1 signals in vehicle-treated SHR were observed than in the same region of WKY rats. The intensity of the immunoreaction was reduced in pravastatin-treated groups compared with that in the vehicle group.

**Correlation.** As shown in Fig. 4, a significant reverse correlation was found between LV weight-indexed body weight and regional ET-1 levels [LV weight/body weight (mg/g) = 0.133 × tissue ET-1 (pg/mg tissue) + 2.642; $r = 0.48$, $P = 0.0004$]. No correlation was detected between LV weight-indexed body weight and blood pressure.

### Table 1. Cardiac morphology, hemodynamics, cholesterol, and plasma and tissue ET-1 concentrations among groups

<table>
<thead>
<tr>
<th>Parameters</th>
<th>SHR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of rats</td>
</tr>
<tr>
<td></td>
<td>Vehicle</td>
</tr>
<tr>
<td>BW, g</td>
<td>10</td>
</tr>
<tr>
<td>LVW/BW, mg/g</td>
<td>325±16</td>
</tr>
<tr>
<td>HR, beats/min</td>
<td>3.03±0.25</td>
</tr>
<tr>
<td>LVEP, mmHg</td>
<td>218±13</td>
</tr>
<tr>
<td>LVEDP, mmHg</td>
<td>6±2</td>
</tr>
<tr>
<td>$+\text{dP/dt}$, mmHg/s</td>
<td>9,108±978</td>
</tr>
<tr>
<td>Plasma cholesterol, mg/dl</td>
<td>6,006±560</td>
</tr>
<tr>
<td>Plasma ET-1, pg/ml</td>
<td>1,42±0.41†</td>
</tr>
<tr>
<td>LV ET-1, pg/mg tissue</td>
<td>2,69±0.70</td>
</tr>
</tbody>
</table>

Values are means ± SD. BW, body weight; ET-1, endothelin-1; HR, heart rate; LVEDP, left ventricular end-diastolic pressure; LVEP, left ventricular end-systolic pressure; LVW, left ventricular weight; Meval, mevalonate; Prav, pravastatin; WKY, Wistar-Kyoto rats. *$P < 0.05$ compared with spontaneously hypertensive rat (SHR) groups. †$P < 0.05$ compared with vehicle-, mevalonate-, combination-, and hydralazine-treated groups. ‡$P < 0.05$ compared with vehicle-, bosentan-, mevalonate-, and combination-treated groups.
study showing that the density of ETB receptor is increased
hypertrophy. Our results were consistent with those of a recent
proET-1 mRNA and ET-1 protein levels, developed ventricular
acting through the corresponding increase of ventricular pre-
observed at the cellular level as well as the organ levels. SHR,
studies (5). Hypertrophic changes in the heart of SHR were
pressure pattern of hypertrophy that is consistent with previous
significantly greater than those in WKY rats. Cell width was
dimensional cell surface area of myocytes in SHR were sig-
morphological methods. First, ET-1 levels are responsible for
findings through combined use of molecular, biochemical, and
vascular stimulation. *P < 0.05 compared with Wistar-Kyoto (WKY) rats,
blood pressure. Thus some factors other than high blood
pressure may contribute to the pathogenesis of cardiac hyper-
trophy in SHR. These findings support the notion that prava-
statin prevents progression of ventricular hypertrophy through attenuation of mevalonate-dependent tissue
Mechanisms. The present study suggests that pravastatin
affects myocyte function (attenuated pacing-induced arrhyth-
ias) and growth (attenuating myocardial hypertrophy). The
mechanisms by which pravastatin attenuates cardiac hypertro-
phy remain to be defined. Clearly, hemodynamics did not play a
major role in the process. Various statins have been shown to
reduce blood pressure in patients (10) and animals (37). Glo-
riso et al. (10) have shown hemodynamic improvement after
16-wk therapy with pravastatin in hypertensive patients. How-
ever, the mechanism by which pravastatin prevents cardiac
hypertrophy is probably not due to its antihypertensive effect
alone. In this study, we found that chronic treatment of SHR
with hydralazine did not prevent ongoing cardiac hypertrophy
even though it was as effective as pravastatin in lowering blood
pressure in SHR. Thus, although we demonstrated hyperkinetic
circulation in relatively young SHR, hemodynamics did not
play a major role in attenuation of cardiac hypertrophy in
pravastatin-treated SHR. Further evidence of this is our finding
that LV weight correlates with tissue ET-1 levels but not with
blood pressure. Thus some factors other than high blood
pressure may contribute to the pathogenesis of cardiac hyper-
trophy in SHR. These findings support the notion that prava-
statin has direct tissue effects dissociated from its hemody-
namic systemic effects.

**DISCUSSIONS**

The present study demonstrates for the first time that prav-
astatin prevents ongoing cardiac hypertrophy at the early hy-
pertrophic phase of SHR, independently of hemodynamic and
lipid changes. The present study demonstrates three novel
findings through combined use of molecular, biochemical, and
morphological methods. First, ET-1 levels are responsible for
ventricular hypertrophy through attenuation of mevalonate-dependent tissue

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Vehicle</th>
<th>Bosentan</th>
<th>Pravastatin</th>
<th>Mevalonate</th>
<th>Prav + Meval</th>
<th>Hydralazine</th>
<th>WKY</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of animals</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Myocyte length, μm</td>
<td>139±27</td>
<td>138±20</td>
<td>135±20</td>
<td>138±25</td>
<td>137±21</td>
<td>138±16</td>
<td>134±15</td>
</tr>
<tr>
<td>Myocyte width, μm</td>
<td>24±3</td>
<td>22±2*</td>
<td>21±2*</td>
<td>26±4</td>
<td>26±3</td>
<td>25±2</td>
<td>21±3*</td>
</tr>
<tr>
<td>Measured myocyte areas, μm²</td>
<td>3,803±213</td>
<td>3,098±146*</td>
<td>3,170±157*</td>
<td>3,647±229</td>
<td>3,561±207</td>
<td>3,872±102</td>
<td>3,010±192*</td>
</tr>
</tbody>
</table>

Values are means ± SD. *P < 0.05 compared with vehicle-, mevalonate-, combination-, and hydralazine-treated groups.

**Table 2. Characteristics of isolated cardiomyocytes**

**Fig. 1. Inducibility quotient of ventricular arrhythmias by programmed electrical stimulation.** *P < 0.05 compared with Wistar-Kyoto (WKY) rats, bosentan-treated spontaneously hypertensive rats (SHR), and pravastatin-treated SHR. Meval, mevalonate; Prav, pravastatin.

**Fig. 2. Left ventricular (LV) preproendothelin-1 (preproET-1) mRNA levels in WKY rats and vehicle-treated, pravastatin-treated, mevalonate-treated, pravastatin + mevalonate (combination)-treated, and hydralazine-treated SHR.** Each mRNA level was corrected for an mRNA level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Values are means ± SD. *P < 0.05 compared with WKY rats. †P < 0.05 compared with vehicle-, mevalonate-, combination-, and hydralazine-treated SHR.
Our observations showed that reduced pravastatin-related ET-1 levels might play crucial roles in attenuation of myocyte hypertrophy. The role of ET-1 in pathogenesis of myocyte hypertrophy was further confirmed by directly blocking ET receptors. Attenuated cardiac hypertrophy accompanied by reduced cardiac ET-1 indicated that autocrine/paracrine ET-1 secretion pathways could be a factor in the proliferative process blunted by pravastatin. The addition of mevalonate to pravastatin-treated rats impaired not only their ability to attenuate cellular hypertrophy but also their ability to suppress ET-1 levels. Thus blocking the mevalonate pathway is a critical step in the mechanism of pravastatin-induced attenuation of ET-1 levels. The molecular mechanism of noncholesterol effects of statins is the inhibition of the isoprenoid intermediates of the cholesterol pathway. Isoprenoids are essential for the function of signal transduction molecules of the Rho family (20). Regulation of Rho activity by statins is separate from that of statins on lipids. Inhibition of Rho signaling by statins can activate peroxisome proliferator-activated receptors (6), which in turn suppress ET-1 secretion (34). In addition, decreases in regional ET-1 concentrations may result from decreases in ET-1 production and/or increased ET-1 clearance. The production of ET-1 begins with the cleavage of the translational product preproET-1. Our results show inhibition of pravastatin on preproET-1 mRNA at the transcription levels. Thus decreases in ET-1 production may play a major role in regional ET-1 changes. Together, both secretion and synthesis of ET-1 may be inhibited after the administration of pravastatin reduces tissue ET-1 levels, which attenuated progression of cardiomyocyte hypertrophy.

There are controversies as to the role of ET-1 in the pathogenesis and maintenance of ventricular hypertrophy in SHR. Some reports have shown that the ET system does not appear to play an important role in ventricular hypertrophy in SHR (25). However, others have suggested a causal role for ET in the development of hypertension in SHR (29). These discrepancies may be due to differences in ages of hypertensive rats that were associated with different pathological and physiological conditions during exposure to different developmental periods. It has been suggested that different stages of hypertension may be differentially regulated in SHR (3). Ito et al. (14) have proposed that cardiac ET-1 may act as an initiating hypertrophic factor during the early stage of pressure overload but that other factors, such as the renin-angiotensin system, may take over as maintaining factors during the late stage of pressure overload. Our studies were performed in quite young animals, i.e., 16-wk old at the end of treatment, in which the development of hypertrophy is at its early stages. Our data are consistent with the notion that early ET-1 production acts as a triggering factor to hypertrophy. Indeed, our results are com-

![Fig. 3. Immunohistochemical microscopy of ET-1 (magnification ×200). Positive staining for ET-1 (brown) was distributed in the myocardium. The intensity of ET-1 was significantly lower in pravastatin-treated SHR (C) than in SHR treated with vehicle (B), mevalonate (D), pravastatin + mevalonate (E), and hydralazine (F). A: WKY rats. Bar, 100 μm.](http://ajpheart.physiology.org/)

AJP-Heart Circ Physiol • VOL 289 • JULY 2005 • www.ajpheart.org
has been shown to induce ET-1 synthesis in cardiomyocytes in vitro (31). Lovastatin has been shown to inhibit activity of angiotensin II (31), thus accounting for the downregulation effect on ET-1 protein expression (7). Although pravastatin has little effect on cardiac angiotensin activity (19), we cannot rule out the possibility of decreased cardiac angiotensin activity secondarily to an inhibition of ET-1 exerted by the agent. Complex interactions among angiotensin II, free radical, nitric oxide, and NADP-isocitrate dehydrogenase activity could affect cardiac hypertrophy. Therefore, a variety of upstream regulators could interfere with hypertrophic signaling pathways. The failure to completely abrogate the hypertrophic process was not surprising in view of the underlying complex hypertrophic process, which is unlikely to be amendable to one therapeutic intervention. Extensive investigation of such pathways and the mechanisms by which pravastatin attenuates cardiac hypertrophy require additional studies.

Arrhythmias. LV hypertrophy is associated with structural, hemodynamic, and electrophysiological abnormalities. Our results showed that attenuated ventricular hypertrophy after pravastatin administration has benefits in the incidence of ventricular arrhythmias. Myocyte hypertrophy may cause a lengthening of action potential duration, which may generate arrhythmias, via downregulation of the transient outward current (I\textsubscript{to}) as well as the delayed and background rectifier current (I\textsubscript{k1}, I\textsubscript{k2}) (18). Rials et al. (33) have shown that regression of cardiac hypertrophy leads to normalization of the prolonged action potential. Furthermore, ET-1 has been shown to directly inhibit potassium channel and act as an important mediator of arrhythmogenesis (17), which was consistent with the antiarrhythmic effect of pravastatin by attenuation of ET-1 levels. In fact, our results were consistent with those of Matsumoto et al. (28), showing that long-term treatment with ET-1 blockers inhibits electrical remodeling and suppresses ventricular arrhythmias. Third, SHR have been shown to have increased sympathetic tone (38), a key trigger of fatal arrhythmias. Statins may decrease ventricular vulnerability by normalizing sympathetic control (32). Together, regardless of the relative importance of each of these factors, all of the changes caused by pravastatin are compatible with our understanding of beneficial effects on induction of ventricular arrhythmias.

Study limitations. A potential problem with the present study is whether cardiomyocytes contribute to increased ET-1 expression. Although immunohistochemical analysis of the LV revealed the presence of ET-1 immunoreactivity in this study, a number of other cell types not normally present in the myocardial tissue to any substantial degree may also produce ET-1 and may contribute to the increased expression during ventricular hypertrophy. These include vascular endothelial cells, smooth muscle cells, and fibroblasts (30). Because we did not perform a double staining for ET-1 and a specific myocyte lineage, we cannot rule out the possibility that non-myocytes may provide an alternative source of ET-1 to initiate ventricular hypertrophy.

In conclusion, the results of the present study show that SHR at the early stage of hypertension have an increase of proET-1 mRNA and the mature ET-1 peptide. The finding can be rationalized mechanistically, suggesting a pathogenetic role of regional ET-1 expression in the development of myocardial hypertrophy. Early intervention with pravastatin can reduce the inducibility of ventricular arrhythmias as a result of attenuated
ventricular hypertrophy, probably through the ET-1 pathway, which is linked to mevalonate metabolism. The pharmacological profile of pravastatin gives new perspectives in the early treatment of ventricular hypertrophy.

ACKNOWLEDGMENTS
We thank In-Ping Cheng, Li-Lan Chien, Shu-Ping Sun, and Fang-Chin Lee for excellent technical assistance and Yu-Wei Chao for performing real-time RT-PCR analysis.

GRANTS
This work was supported by Chi-Mei Medical Center Grants CMHFT 9201, CMHR9303, CMHR9307, and CM-TMU9305. Bosentan was a generous gift from Actelion Pharmaceuticals Ltd., Allschwil, Switzerland. Pravastatin was a generous gift from Sankyo Pharmaceuticals Ltd., Tokyo, Japan.

REFERENCES


